RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Evaluation of a Novel Antiplatelet Agent for Secondary Prevention in Patients with Atherosclerotic Disease: Results from the TRA 2P-TIMI 50 Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 4
SP 19
OP 19
DO 10.1177/155989771204012
UL http://mdc.sagepub.com/content/12/4/19.1.abstract
AB In stable patients with a history of atherosclerosis, the investigational protease-activated receptor (PAR)-1 antagonist vorapaxar was effective at reducing further atherothrombotic events. This article presents data from the Thrombin Receptor Antagonist in Secondary Prevention-TIMI 50 Trial [TRA 2P; NCT00526474] which showed that vorapaxar significantly reduced the risk of deaths from cardiovascular disease, myocardial infarction, or stroke compared with placebo.